Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats

In conclusion, our results demonstrate that the combined therapy of spironolactone and candesartan can confer an additive benefit over the use of either drug alone against STZ-induced diabetic nephropathy, presumably via attenuating the inflammatory responses and oxidative status markers.